Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective treatments for obesity, but discontinuation is common due to cost, insurance coverage limitations, side effects, patient preference, and other factors. Weight regain often occurs rapidly after cessation, yet few evidence-based strategies exist to support weight maintenance during this transition. This pilot randomized trial examined whether a… Continue reading Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial
Tag: GLP-1
Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation
Background: Rheumatoid arthritis (RA)-related physical limitations often hinder sustained physical activity and weight management, thereby amplifying cardiovascular risk through adverse metabolic profiles and chronic inflammation. We aimed to assess the effectiveness of semaglutide on the risk of incident major adverse cardiovascular and cerebrovascular events (MACCE) in obese adults with type 2 diabetes mellitus (T2DM) and… Continue reading Semaglutide for Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Patients with Type 2 Diabetes and Comorbid Rheumatoid Arthritis: A Target-Trial Emulation
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Importance: #Psoriasis is a chronic immune-mediated disease associated with cardiovascular, metabolic, musculoskeletal, psychiatric, hepatic, kidney, and pulmonary comorbidities. Glucagon-like peptide-1 receptor agonists (#GLP-1 RAs) are approved by the US Food and Drug Administration for type 2 diabetes, obesity, cardiovascular risk reduction, chronic kidney disease, obstructive sleep apnea, and metabolic dysfunction-associated steatohepatitis-conditions common in psoriasis. Emerging… Continue reading The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Effects of glucagon-like peptide-1 on systemic hemodynamics, kidney function, and intrarenal oxygenation in sheep with sepsis-associated acute kidney injury
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce chronic kidney disease progression in people with type 2 diabetes mellitus. Sepsis is the leading cause of acute kidney injury (AKI). This study investigated whether GLP-1 is renoprotective in an ovine model of gram-negative septic AKI. Sixteen healthy merino ewes were surgically instrumented to measure mean arterial pressure,… Continue reading Effects of glucagon-like peptide-1 on systemic hemodynamics, kidney function, and intrarenal oxygenation in sheep with sepsis-associated acute kidney injury
Dual target, dual benefit: real-world effects of #SGLT2 inhibitors and #GLP-1 receptor agonists on the FIB-4 score in people with type 2 #diabetes mellitus
Liver fibrosis is a serious comorbidity of type 2 diabetes mellitus (T2DM) in which non-invasive indices such as FIB-4 are used to monitor hepatic health. This study assesses the impact of GLP-1 receptor agonists (GLP-1RA), SGLT2 inhibitors (SGLT2i), and their combinations on FIB-4 scores in people with T2DM.MethodsWe conducted a retrospective analysis of 133 adults… Continue reading Dual target, dual benefit: real-world effects of #SGLT2 inhibitors and #GLP-1 receptor agonists on the FIB-4 score in people with type 2 #diabetes mellitus
The effects of glucagon-like peptide-1 receptor agonists (#GLP1-RAs ) on #alcohol -related outcomes: a systematic review and meta-analysis
Objective: To evaluate the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on alcohol-related outcomes in adults with or without alcohol use disorder (AUD).Methods: A systematic review and meta-analysis following PRISMA guidelines searched PubMed, Embase, and Cochrane Library up to May 3, 2025. Eligible studies included randomized controlled trials (RCTs) and observational studies assessing GLP-1RAs (e.g.,… Continue reading The effects of glucagon-like peptide-1 receptor agonists (#GLP1-RAs ) on #alcohol -related outcomes: a systematic review and meta-analysis
#Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related #Macular #Degeneration
Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are extensively used in treating diabetes and obesity, yet little is known about the long-term ocular effects of systemic prolonged exposure.Objective To evaluate the risk of developing neovascular age-related macular degeneration (nAMD) associated with the use of GLP-1 RAs in patients with diabetes.Design, Setting, and Participants This population-based,… Continue reading #Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related #Macular #Degeneration
GLP-1RA and SGLT2i Medications for Type 2 #Diabetes and #Alzheimer Disease and Related Dementias
Importance The association between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) and risk of Alzheimer disease and related dementias (ADRD) remains to be confirmed.Objective To assess the risk of ADRD associated with GLP-1RAs and SGLT2is in people with type 2 diabetes (T2D).Design, Setting, and Participants This target trial emulation study used electronic… Continue reading GLP-1RA and SGLT2i Medications for Type 2 #Diabetes and #Alzheimer Disease and Related Dementias
Glucagon-Like Peptide-1 Receptor Agonists and Risk for #Depression in Older Adults With Type 2 #Diabetes
Background:Although glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential antidepressant effects, population studies yield inconsistent results. Objective:To compare the risk for depression in older adults with type 2 diabetes (T2D) initiating treatment with GLP-1RAs versus sodium–glucose cotransporter-2 inhibitors (SGLT2is) or dipeptidyl peptidase-4 inhibitors (DPP4is).Design:Target trial emulation study.Setting:U.S. National Medicare administrative data from January 2014 to… Continue reading Glucagon-Like Peptide-1 Receptor Agonists and Risk for #Depression in Older Adults With Type 2 #Diabetes
